- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Bristol Myers' beat completes strong week of pharma earnings | ||
| Fr | Two biotechs cut staff; AbbVie weathers biosimilar threat | ||
| Fr | Leqembi voted down by European regulators | ||
| Do | Roche says it'll move quickly with 'differentiated' obesity drugs | ||
| Do | Sanofi's immunology bet starts to pay off | ||
| Do | Warren, Democratic lawmakers introduce bill to resurrect Chevron doctrine | ||
| Do | Viking shares jump on plans to speed obesity drug into late-stage testing | ||
| Mi | Biogen, Sage tremor drug fails key trial | ||
| Mi | PBMs battle bipartisan scrutiny as lawmakers eye reforms | ||
| Mi | FDA medical device chief Shuren to step down after 15 years | ||
| Mi | Pfizer says hemophilia gene therapy meets late-stage study goal | ||
| Mi | Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board | ||
| Mi | Autobahn raises $100M on investor interest in neuropsych drugs | ||
| Di | Merck claims late-stage study success for RSV antibody | ||
| Di | Startup led by former J&J executives raises $165M for cancer, immune disease drugs | ||
| Di | US government declines to clear Bluebird fertility support for Zynteglo patients | ||
| Mo | Ionis plots next steps for Angelman drug Biogen passed on | ||
| Mo | J&J seeks expanded approval for antidepressant Spravato | ||
| Mo | Private biotech M&A surges amid difficult IPO market | ||
| Mo | Clinical data registries: Transforming the future of medical research | ||
| Mo | Breakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response | ||
| 19.07. | Global tech outage hits US hospitals | ||
| 19.07. | Lilly alone in bidding for Morphic; Novartis won't yet file MorphoSys drug | ||
| 19.07. | Artiva prices $167M IPO, riding optimism for autoimmune cell therapy | ||
| 18.07. | Boehringer cuts price of Humira biosimilar in bid to build use |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
